TherapeuticsMD Analyst Ratings
TherapeuticsMD Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 01/11/2023 | -11.35% | Cantor Fitzgerald | → $5 | Reinstates | → Neutral |
| 07/13/2022 | -82.27% | Cantor Fitzgerald | → $1 | Reiterates | → Neutral |
| 06/07/2022 | 77.3% | HC Wainwright & Co. | → $10 | Downgrades | Buy → Neutral |
| 05/06/2022 | -82.27% | Cantor Fitzgerald | $5 → $1 | Downgrades | Overweight → Neutral |
| 03/11/2022 | -55.67% | HC Wainwright & Co. | $3 → $2.5 | Maintains | Buy |
| 11/12/2021 | -46.81% | HC Wainwright & Co. | $4 → $3 | Maintains | Buy |
| 08/07/2020 | -78.72% | Jefferies | $1.25 → $1.2 | Downgrades | Hold → Underperform |
| 05/19/2020 | — | JP Morgan | Downgrades | Overweight → Neutral | |
| 05/07/2020 | -11.35% | HC Wainwright & Co. | $6 → $5 | Reiterates | → Buy |
| 04/16/2020 | 165.96% | Stifel | $14 → $15 | Maintains | Buy |
| 02/21/2020 | 6.38% | HC Wainwright & Co. | $7 → $6 | Maintains | Buy |
| 08/14/2018 | 378.72% | Cantor Fitzgerald | $26 → $27 | Maintains | Overweight |
| 06/15/2018 | 95.04% | JP Morgan | → $11 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 2023年1月11日 | -11.35% | 康托·菲茨杰拉德 | →$5 | 恢复 | →中性 |
| 07/13/2022 | -82.27% | 康托·菲茨杰拉德 | →$1 | 重申 | →中性 |
| 06/07/2022 | 77.3% | HC Wainwright公司 | →$10 | 评级下调 | 购买→中性 |
| 05/06/2022 | -82.27% | 康托·菲茨杰拉德 | $5→$1 | 评级下调 | 超重→中性 |
| 03/11/2022 | -55.67% | HC Wainwright公司 | $3→$2.5 | 维护 | 买 |
| 2021年11月12日 | -46.81% | HC Wainwright公司 | $4→$3 | 维护 | 买 |
| 08/07/2020 | -78.72% | 杰富瑞 | $1.25→$1.2 | 评级下调 | 持有→表现不佳 |
| 2020/05/19 | - | 摩根大通 | 评级下调 | 超重→中性 | |
| 05/07/2020 | -11.35% | HC Wainwright公司 | $6→$5 | 重申 | →购买 |
| 04/16/2020 | 165.96% | Stifel | $14→$15 | 维护 | 买 |
| 02/21/2020 | 6.38% | HC Wainwright公司 | $7→$6 | 维护 | 买 |
| 2018年08月14日 | 378.72% | 康托·菲茨杰拉德 | $26→$27 | 维护 | 超重 |
| 2018年06月15日 | 95.04% | 摩根大通 | →$11 | 开始承保 | →超重 |
What is the target price for TherapeuticsMD (TXMD)?
TreateuticsMD(TXMD)的目标价格是多少？
The latest price target for TherapeuticsMD (NASDAQ: TXMD) was reported by Cantor Fitzgerald on January 11, 2023. The analyst firm set a price target for $5.00 expecting TXMD to fall to within 12 months (a possible -11.35% downside). 5 analyst firms have reported ratings in the last year.
康托·菲茨杰拉德于2023年1月11日报道了TreateuticsMD(纳斯达克：TXMD)的最新目标价。这家分析公司将目标价定为5美元，预计TXMD将在12个月内降至(可能下跌11.35%)。去年有5家分析公司公布了评级。
What is the most recent analyst rating for TherapeuticsMD (TXMD)?
最近分析师对TreateuticsMD(TXMD)的评级是多少？
The latest analyst rating for TherapeuticsMD (NASDAQ: TXMD) was provided by Cantor Fitzgerald, and TherapeuticsMD their neutral rating.
对TreateuticsMD(纳斯达克代码：TXMD)的最新分析师评级由坎托·菲茨杰拉德提供，TreateuticsMD的评级为中性。
When is the next analyst rating going to be posted or updated for TherapeuticsMD (TXMD)?
下一次分析师对TreateuticsMD(TXMD)的评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of TherapeuticsMD, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for TherapeuticsMD was filed on January 11, 2023 so you should expect the next rating to be made available sometime around January 11, 2024.
分析师在进行了广泛的研究后得出股票评级，其中包括查看公共财务报表，与TreeuticsMD的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。TreeuticsMD的上一次评级是在2023年1月11日提交的，所以你应该预计下一次评级将在2024年1月11日左右提供。
Is the Analyst Rating TherapeuticsMD (TXMD) correct?
分析师对TreeuticsMD(TXMD)的评级正确吗？
While ratings are subjective and will change, the latest TherapeuticsMD (TXMD) rating was a with a price target of $0.00 to $5.00. The current price TherapeuticsMD (TXMD) is trading at is $5.64, which is out of the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的治疗MD(TXMD)评级为A，目标价在0.00美元至5.00美元之间。TreateuticsMD(TXMD)目前的交易价格为5.64美元，超出了分析师的预测范围。